Skip to main content
Erschienen in: Tumor Biology 1/2014

01.01.2014 | Research Article

Association between myeloperoxidase G-463A polymorphism and lung cancer risk

verfasst von: Chao Huang, Lu Ma, Dejia Li

Erschienen in: Tumor Biology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Many epidemiologic studies have investigated the association between myeloperoxidase (MPO) G-463A polymorphism and lung cancer risk, but the results were controversial. We performed a meta-analysis of 25 studies on MPO polymorphism and lung cancer risk published before July 2013. The allele of A was found to be associated with decreased risk of lung cancer compared with G allele (OR, 0.90; 95 % CI, 0.82–0.98) in the general population. The significant association remained in the comparison between AA + AG and GG (OR, 0.92; 95 % CI, 0.87–0.98). When it was stratified according to Asian population, the association between MPO polymorphism and lung cancer risk was further strengthened. However, no associations were found in the Caucasian population. This meta-analysis has demonstrated that MPO polymorphism might contribute to individual’s susceptibility to lung cancer in Asian population. Caucasian authors could re-investigate the association between MPO polymorphism and lung cancer risk with more specific participants. Future studies focusing on interactions between combined genes and environmental risk factors are warranted.
Literatur
1.
Zurück zum Zitat Lee PN. Relation between exposure to asbestos and smoking jointly and the risk of lung cancer. Occup Environ Med. 2001;58:145–53.PubMedCrossRef Lee PN. Relation between exposure to asbestos and smoking jointly and the risk of lung cancer. Occup Environ Med. 2001;58:145–53.PubMedCrossRef
2.
Zurück zum Zitat Alberg AJ, Ford JG, Samet JM, American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29S–55S.PubMedCrossRef Alberg AJ, Ford JG, Samet JM, American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29S–55S.PubMedCrossRef
3.
Zurück zum Zitat Marshall AL, Christiani DC. Genetic susceptibility to lung cancer—light at the end of the tunnel? Carcinogenesis. 2013;34:487–502.PubMedCrossRef Marshall AL, Christiani DC. Genetic susceptibility to lung cancer—light at the end of the tunnel? Carcinogenesis. 2013;34:487–502.PubMedCrossRef
5.
Zurück zum Zitat Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant—463a of the myeloperoxidase gene. Cancer Res. 2000;60:644–9.PubMed Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant—463a of the myeloperoxidase gene. Cancer Res. 2000;60:644–9.PubMed
6.
Zurück zum Zitat Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Nqo1, mpo, and the risk of lung cancer: a huge review. Genet Med. 2005;7:463–78.PubMedCrossRef Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Nqo1, mpo, and the risk of lung cancer: a huge review. Genet Med. 2005;7:463–78.PubMedCrossRef
7.
Zurück zum Zitat Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, et al. Myeloperoxidase g-463a polymorphism and lung cancer: a huge genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. 2007;9:67–73.PubMedCrossRef Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, et al. Myeloperoxidase g-463a polymorphism and lung cancer: a huge genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. 2007;9:67–73.PubMedCrossRef
8.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
9.
Zurück zum Zitat Lu W, Xing D, Qi J, Tan W, Miao X, Lin D. Genetic polymorphism in myeloperoxidase but not gstm1 is associated with risk of lung squamous cell carcinoma in a Chinese population. Int J Cancer. 2002;102:275–9.PubMedCrossRef Lu W, Xing D, Qi J, Tan W, Miao X, Lin D. Genetic polymorphism in myeloperoxidase but not gstm1 is associated with risk of lung squamous cell carcinoma in a Chinese population. Int J Cancer. 2002;102:275–9.PubMedCrossRef
10.
Zurück zum Zitat Wu XM, Zhou YK, Ren S. Hao QL: [gene polymorphism of myeloperoxidase and genetic susceptibility to lung cancer]. Ai Zheng. 2003;22:912–5.PubMed Wu XM, Zhou YK, Ren S. Hao QL: [gene polymorphism of myeloperoxidase and genetic susceptibility to lung cancer]. Ai Zheng. 2003;22:912–5.PubMed
11.
Zurück zum Zitat Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the gstm1, gstp1, mpo, xrcc1, and nqo1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the cdkn2a and rarb genes. Cancer Genet Cytogenet. 2005;162:10–20.PubMedCrossRef Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the gstm1, gstp1, mpo, xrcc1, and nqo1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the cdkn2a and rarb genes. Cancer Genet Cytogenet. 2005;162:10–20.PubMedCrossRef
12.
Zurück zum Zitat Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase-463g > a polymorphism and risk of primary lung cancer in a Korean population. Cancer Detect Prev. 2006;30:257–61.PubMedCrossRef Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase-463g > a polymorphism and risk of primary lung cancer in a Korean population. Cancer Detect Prev. 2006;30:257–61.PubMedCrossRef
13.
Zurück zum Zitat Zhang T, Hong X, Wu Y, Wu Y. Myeloperoxidase polymorphism in lung cancer patients of Henan Han population. Journal of Zhengzhou University. 2007;42:448–50. Zhang T, Hong X, Wu Y, Wu Y. Myeloperoxidase polymorphism in lung cancer patients of Henan Han population. Journal of Zhengzhou University. 2007;42:448–50.
14.
Zurück zum Zitat Yang M, Choi Y, Hwangbo B, Lee JS. Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer. 2007;57:135–42.PubMedCrossRef Yang M, Choi Y, Hwangbo B, Lee JS. Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer. 2007;57:135–42.PubMedCrossRef
15.
Zurück zum Zitat Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. Cyp1b1, cyp1a1, mpo, and gstp1 polymorphisms and lung cancer risk in never-smoking korean women. Lung Cancer. 2008;60:40–6.PubMedCrossRef Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. Cyp1b1, cyp1a1, mpo, and gstp1 polymorphisms and lung cancer risk in never-smoking korean women. Lung Cancer. 2008;60:40–6.PubMedCrossRef
16.
Zurück zum Zitat Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000;21:1163–6.PubMedCrossRef Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000;21:1163–6.PubMedCrossRef
17.
Zurück zum Zitat Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, et al. Counterpoint: the myeloperoxidase-463g—a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002;11:1555–9.PubMed Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, et al. Counterpoint: the myeloperoxidase-463g—a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002;11:1555–9.PubMed
18.
Zurück zum Zitat Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, et al. Point: myeloperoxidase-463g—a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1550–4.PubMed Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, et al. Point: myeloperoxidase-463g—a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1550–4.PubMed
19.
Zurück zum Zitat Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, et al. Myeloperoxidase (mpo) genotype and lung cancer histologic types: the mpo-463 a allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer. 2002;102:530–5.PubMedCrossRef Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, et al. Myeloperoxidase (mpo) genotype and lung cancer histologic types: the mpo-463 a allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer. 2002;102:530–5.PubMedCrossRef
20.
Zurück zum Zitat Schabath MB, Spitz MR, Delclos GL, Gunn GB, Whitehead LW, Wu X. Association between asbestos exposure, cigarette smoking, myeloperoxidase (mpo) genotypes, and lung cancer risk. Am J Ind Med. 2002;42:29–37.PubMedCrossRef Schabath MB, Spitz MR, Delclos GL, Gunn GB, Whitehead LW, Wu X. Association between asbestos exposure, cigarette smoking, myeloperoxidase (mpo) genotypes, and lung cancer risk. Am J Ind Med. 2002;42:29–37.PubMedCrossRef
21.
Zurück zum Zitat Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, et al. Myeloperoxidase-463 (g–a) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc. 2002;77:17–22.PubMedCrossRef Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, et al. Myeloperoxidase-463 (g–a) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc. 2002;77:17–22.PubMedCrossRef
22.
Zurück zum Zitat Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, Barrett M, et al. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett. 2001;164:161–7.PubMedCrossRef Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, Barrett M, et al. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett. 2001;164:161–7.PubMedCrossRef
23.
Zurück zum Zitat Chevrier I, Stucker I, Houllier AM, Cenee S, Beaune P, Laurent-Puig P, et al. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics. 2003;13:729–39.PubMedCrossRef Chevrier I, Stucker I, Houllier AM, Cenee S, Beaune P, Laurent-Puig P, et al. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics. 2003;13:729–39.PubMedCrossRef
24.
Zurück zum Zitat Cajas-Salazar N, Sierra-Torres CH, Salama SA, Zwischenberger JB, Au WW. Combined effect of mpo, gstm1 and gstt1 polymorphisms on chromosome aberrations and lung cancer risk. Int J Hyg Environ Health. 2003;206:473–83.PubMedCrossRef Cajas-Salazar N, Sierra-Torres CH, Salama SA, Zwischenberger JB, Au WW. Combined effect of mpo, gstm1 and gstt1 polymorphisms on chromosome aberrations and lung cancer risk. Int J Hyg Environ Health. 2003;206:473–83.PubMedCrossRef
25.
Zurück zum Zitat Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, et al. Mpo and sod2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004;214:69–79.PubMedCrossRef Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, et al. Mpo and sod2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004;214:69–79.PubMedCrossRef
26.
Zurück zum Zitat Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004;44:74–82.PubMedCrossRef Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004;44:74–82.PubMedCrossRef
27.
Zurück zum Zitat Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM. Cyp1a1 ile462val and mpo g-463a interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis. 2006;27:525–32.PubMedCrossRef Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM. Cyp1a1 ile462val and mpo g-463a interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis. 2006;27:525–32.PubMedCrossRef
28.
Zurück zum Zitat Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, et al. A comprehensive analysis of phase i and phase ii metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29:1164–9.PubMedCrossRef Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, et al. A comprehensive analysis of phase i and phase ii metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29:1164–9.PubMedCrossRef
29.
Zurück zum Zitat Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, et al. Phase i metabolic genes and risk of lung cancer: multiple polymorphisms and mrna expression. PLoS One. 2009;4:e5652.PubMedCentralPubMedCrossRef Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, et al. Phase i metabolic genes and risk of lung cancer: multiple polymorphisms and mrna expression. PLoS One. 2009;4:e5652.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase g-463a polymorphism and risk of lung and prostate cancer in a Turkish population. Mol Med Rep. 2011;4:87–92.PubMed Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase g-463a polymorphism and risk of lung and prostate cancer in a Turkish population. Mol Med Rep. 2011;4:87–92.PubMed
31.
Zurück zum Zitat London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997;57:5001–3.PubMed London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997;57:5001–3.PubMed
32.
Zurück zum Zitat Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase -463g–a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:181–4.PubMed Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase -463g–a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:181–4.PubMed
33.
Zurück zum Zitat Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health. 1987;77:425–31.PubMedCrossRef Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health. 1987;77:425–31.PubMedCrossRef
34.
Zurück zum Zitat Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case–control studies. BMJ. 2000;321:323–9.PubMedCrossRef Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case–control studies. BMJ. 2000;321:323–9.PubMedCrossRef
35.
Zurück zum Zitat Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191–308.PubMed Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191–308.PubMed
36.
Zurück zum Zitat Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis. 2007;28:507–18.PubMedCrossRef Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis. 2007;28:507–18.PubMedCrossRef
37.
Zurück zum Zitat Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009;85:679–91.PubMedCentralPubMedCrossRef Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009;85:679–91.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Ito H, McKay JD, Hosono S, Hida T, Yatabe Y, Mitsudomi T, et al. Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population. J Thorac Oncol. 2012;7:790–8.PubMedCrossRef Ito H, McKay JD, Hosono S, Hida T, Yatabe Y, Mitsudomi T, et al. Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population. J Thorac Oncol. 2012;7:790–8.PubMedCrossRef
39.
Zurück zum Zitat de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, et al. Association between egf +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case–control study. Tumour Biol. 2012;33:1341–8.PubMedCrossRef de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, et al. Association between egf +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case–control study. Tumour Biol. 2012;33:1341–8.PubMedCrossRef
Metadaten
Titel
Association between myeloperoxidase G-463A polymorphism and lung cancer risk
verfasst von
Chao Huang
Lu Ma
Dejia Li
Publikationsdatum
01.01.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1067-6

Weitere Artikel der Ausgabe 1/2014

Tumor Biology 1/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.